Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with
placebo in patients with chronic constipation (CC) and prominent abdominal bloating. This
study includes an up to 3-week screening period and a 2-3 week pretreatment period. Patients
who are eligible will be randomized to one of two doses of linaclotide or placebo for 12
weeks. This 12-week study will assess the effects of linaclotide on bowel movement frequency,
as well as other abdominal and bowel symptoms of CC.